top of page
Browse by category
Search
REDEFINE 1 trial: CagriSema demonstrates superior weight loss in adults with obesity or overweight
Headline results from Novo Nordisk’s REDEFINE 1 has shown that the trial achieved its primary endpoint by demonstrating a statistically...
Zepbound (tirzepatide) is the first and only FDA approved prescription medicine for moderate-to-severe OSA in adults with obesity
The FDA has approved Eli Lilly and Company’s Zepbound (tirzepatide) as the first and only prescription medicine for adults with...
Preoperative antihypertensive drugs and visceral fat area can predict hypertension remission and recurrence post-LSG
By combining the number of preoperative antihypertensive drugs (ADs) and visceral fat area (VFA) may help predict hypertension (HTN)...
Muscle-preserving weight loss drug ASC47 plus semaglutide is superior to semaglutide monotherapy for weight loss
Ascletis Pharma has revealed in a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg,...
Racial and ethnic groups face barriers to obtaining OMMs
Asians, non-Hispanic Blacks and Hispanics were significantly less likely than whites to use obesity-management medications (OMMs) to...
Survey finds 50% of post-bariatric surgery patients feel less stress during the holidays
About 50% of bariatric patients reported experiencing significantly less or less stress during the holidays compared to the holiday...
Browse by tag
bottom of page